Health CatalystHCAT -1.71%49 EBITDA Margin % is -132.50% as of Mar. 2026. GuruFocus rates HCAT with a GF Score™ of 49/100 and a GF Value™ of $5.07 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Health Catalyst ranks worse than 89.67% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Health Catalyst's EBITDA for the
three
months ended in Mar. 2026 was $-93.8 Mil. Health Catalyst's Revenue for the
three
months ended in Mar. 2026 was $70.8 Mil. Therefore, Health Catalyst's EBITDA margin for the quarter that ended in Mar. 2026 was -132.50%.
Health Catalyst (NAS:HCAT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Health Catalyst EBITDA Margin % Related Terms
Health Catalyst EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Health Catalyst's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCAT vs CCLD, DH, OPRX: EBITDA Margin % Comparison
For the Health Information Services subindustry, Health Catalyst's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Health Catalyst EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Health Catalyst's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Health Catalyst's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Health Catalyst (HCAT) has a EBITDA Margin % of -132.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Health Catalyst and its competitors. According to the industry distribution chart, Health Catalyst ranks #599 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 89.7%.
Is Health Catalyst's EBITDA Margin % too high?
Health Catalyst's current EBITDA Margin % is -132.50%. Based on the distribution chart, Health Catalyst ranks #599 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Health Catalyst has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Health Catalyst's EBITDA Margin % compare to CCLD and DH?
According to the Healthcare Providers & Services industry distribution chart, Health Catalyst ranks #599 out of 668 companies for EBITDA Margin %. This places Health Catalyst in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Health Catalyst and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Health Catalyst's current EBITDA Margin % is -132.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Catalyst stock overvalued right now?
Based on GuruFocus' analysis, Health Catalyst (HCAT) is currently considered Possible Value Trap. The stock's GF Value™ is $5.07, compared to a current price of $1.72 — trading 66.1% below its estimated fair value. The current EBITDA Margin % is -132.50%. Health Catalyst's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Health Catalyst (HCAT), the current EBITDA Margin % is -132.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Health Catalyst (HCAT) Overvalued in 2026?
Based on GuruFocus' analysis, Health Catalyst stock appears to be undervalued.
The current stock price of $1.72 is trading 66.1% below its estimated GF Value™ of $5.07.
GuruFocus considers Health Catalyst to be Possible Value Trap.
Key valuation signals for HCAT:
EBITDA Margin %: -132.50%
GF Value™: $5.07 vs. price of $1.72 (66.1% below fair value)
No single metric tells the full story. See the HCAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
49GF Score
Get the complete analysis for HCAT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCAT has been successfully added to your 
